enGene Therapeutics Future Growth
Future criteria checks 2/6
enGene Therapeutics is forecast to grow earnings and revenue by 8.8% and 64.3% per annum respectively. EPS is expected to grow by 22.3% per annum. Return on equity is forecast to be -101.6% in 3 years.
Key information
8.8%
Earnings growth rate
22.28%
EPS growth rate
| Biotechs earnings growth | 25.2% |
| Revenue growth rate | 64.3% |
| Future return on equity | -101.60% |
| Analyst coverage | Good |
| Last updated | 14 May 2026 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 10/31/2028 | 35 | -145 | -149 | -139 | 9 |
| 10/31/2027 | 8 | -154 | -155 | -133 | 9 |
| 10/31/2026 | N/A | -135 | -137 | -123 | 9 |
| 1/31/2026 | N/A | -122 | -104 | -102 | N/A |
| 10/31/2025 | N/A | -117 | -101 | -99 | N/A |
| 7/31/2025 | N/A | -95 | -95 | -94 | N/A |
| 4/30/2025 | N/A | -80 | -76 | -75 | N/A |
| 1/31/2025 | N/A | -69 | -67 | -67 | N/A |
| 10/31/2024 | N/A | -55 | -49 | -48 | N/A |
| 7/31/2024 | N/A | -123 | -36 | -35 | N/A |
| 4/30/2024 | N/A | -115 | -37 | -36 | N/A |
| 1/31/2024 | N/A | -107 | -27 | -26 | N/A |
| 10/31/2023 | N/A | -105 | -25 | -25 | N/A |
| 7/31/2023 | N/A | -31 | -24 | -23 | N/A |
| 4/30/2023 | N/A | -32 | -21 | -21 | N/A |
| 1/31/2023 | N/A | -32 | -20 | -20 | N/A |
| 10/31/2022 | N/A | -29 | -18 | -18 | N/A |
| 10/31/2021 | N/A | -22 | -16 | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ENGN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ENGN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ENGN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ENGN's revenue (64.3% per year) is forecast to grow faster than the US market (11.7% per year).
High Growth Revenue: ENGN's revenue (64.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ENGN is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/25 00:11 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/01/31 |
| Annual Earnings | 2025/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
enGene Therapeutics Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jie Cheng | CGS International |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Michael Schmidt | Guggenheim Securities, LLC |